enVVeno Medical Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de enVVeno Medical de 58.6% y 95.9% respectivamente, mientras que el BPA crecerá en un 68.9% al año.

Información clave

64.1%

Tasa de crecimiento de los beneficios

71.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.9%
Tasa de crecimiento de los ingresos	105.8%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	08 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

Mar 07

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:NVNO - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	57	9	N/A	11	1
12/31/2025	24	-15	N/A	-6	1
12/31/2024	N/A	-26	N/A	-19	1
3/31/2024	N/A	-22	-17	-17	N/A
12/31/2023	N/A	-24	-19	-19	N/A
9/30/2023	N/A	-24	-18	-18	N/A
6/30/2023	N/A	-25	-18	-18	N/A
3/31/2023	N/A	-26	-17	-17	N/A
12/31/2022	N/A	-25	-16	-16	N/A
9/30/2022	N/A	-27	-15	-15	N/A
6/30/2022	N/A	-24	-13	-13	N/A
3/31/2022	N/A	-19	-12	-11	N/A
12/31/2021	N/A	-17	-12	-12	N/A
9/30/2021	N/A	-12	-12	-11	N/A
6/30/2021	N/A	-12	-12	-12	N/A
3/31/2021	N/A	-11	-11	-10	N/A
12/31/2020	N/A	-10	-8	-8	N/A
9/30/2020	N/A	-7	-7	-7	N/A
6/30/2020	N/A	-7	-6	-5	N/A
3/31/2020	N/A	-7	-6	-6	N/A
12/31/2019	0	-8	-6	-6	N/A
9/30/2019	0	-7	-6	-6	N/A
6/30/2019	0	-7	-6	-6	N/A
3/31/2019	0	-13	-6	-6	N/A
12/31/2018	0	-16	-6	-6	N/A
9/30/2018	0	-18	-6	-6	N/A
6/30/2018	0	-19	-6	-6	N/A
3/31/2018	0	-12	-5	-5	N/A
12/31/2017	0	-8	N/A	-4	N/A
9/30/2017	1	-7	N/A	-4	N/A
6/30/2017	1	-5	N/A	-3	N/A
3/31/2017	1	-6	N/A	-3	N/A
12/31/2016	1	-6	N/A	-3	N/A
9/30/2016	0	-5	N/A	-4	N/A
12/31/2015	N/A	-1	N/A	-2	N/A
12/31/2014	0	-1	N/A	0	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que NVNO siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que NVNO siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que NVNO siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (105.8% al año) de NVNO crezcan más rápidamente que los del mercado US (8.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (105.8% al año) de NVNO crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de NVNO se prevé que sea elevada dentro de 3 años.

enVVeno Medical Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2026

Price target decreased by 15% to US$20.40

Price target decreased to US$24.00

No longer forecast to breakeven

Price target decreased to US$26.00

Forecast to breakeven in 2024

Recent updates

enVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024

enVVeno Medical Corporation Appoints Andrew Cormack as Its Chief Commercial Officer

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

enVVeno Medical Corporation Announces the Presentation of Positive Topline Efficacy Data Showing Significant Clinical Improvement from the Savve U.S. Pivotal Trial for the Venovalve

New minor risk - Share price stability

Forecast to breakeven in 2026

enVVeno Medical Corporation Presents Positive Preliminary Device Related Material Adverse Event Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium

enVVeno Medical Corporation, Annual General Meeting, Dec 05, 2023

New minor risk - Shareholder dilution

Price target decreased by 15% to US$20.40

enVVeno Medical Corporation Achieves Full Enrollment for VenoValve U.S. Pivotal Trial

Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?

New major risk - Share price stability

Envveno Medical Corporation Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study

New minor risk - Share price stability

Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?

Envveno Medical Promotes Hamed Alavi to Senior Vice President and Chief Technology Officer

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Envveno Medical Corporation Presents Positive Long-Term, Three-Year Observational Data from A Cohort of Patients That Participated in the Previously Concluded Venovalve First-In-Human Clinical Tria

Insufficient new directors

enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study

enVVeno Medical Corporation, Annual General Meeting, Nov 30, 2022

Insufficient new directors

Insufficient new directors

enVVeno Medical: Unique Exposure To Venous Treatment Domain

We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely

enVVeno Medical reports Q2 results

We Think enVVeno Medical (NASDAQ:NVNO) Can Afford To Drive Business Growth

Price target decreased to US$24.00

No longer forecast to breakeven

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Hancock Jaffe Laboratories, Inc Begins Enrollment for the U.S. Pivotal Trial for the Venovalve, Potential Treatment for Deep Venous Chronic Venous Insufficiency

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Price target decreased to US$26.00

Forecast to breakeven in 2024

New 90-day low: US$7.37

Price target lowered to US$28.00

Hancock Jaffe Laboratories, Inc. has completed a Composite Units Offering in the amount of $35.999992 million.

Hancock Jaffe Laboratories, Inc. Appoints Craig Glynn Chief Financial Officer

Hancock Jaffe Laboratories finance chief sheds interim tag

Hancock Jaffe Receives Formal Notification from the Nasdaq Hearings Panel

Hancock Jaffe approves 1:25 reverse stock split

Hancock Jaffe Laboratories, Inc. announced delayed 10-Q filing

Hancock Jaffe Laboratories, Inc., Annual General Meeting, Dec 17, 2020

Hancock Jaffe Laboratories, Inc. (NasdaqCM:HJLI) entered into non-binding letter of intent to acquire Catheter Precision, Inc.

New 90-day high - US$0.56

New 90-day low - US$0.31

Hancock Jaffe Regains Compliance with Nasdaq Stockholder's Equity Rule

New 90-day low - US$0.31

Hancock Jaffe Laboratories, Inc. announced that it has received $1.556 million in funding

Hancock Jaffe Laboratories, Inc. has completed a Composite Units Offering in the amount of $4 million.

Hancock Jaffe Laboratories, Inc. announced that it expects to receive $1.556 million in funding

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento